Fluorine-18-fluorodeoxyglucose positron emission tomography in technetium-99m-hydroxymethylenediphosphate negative bone tumors.
We have encountered two cases of bone tumors with high 18F-fluorodeoxyglucose (FDG) uptake and negative 99mTc-HMDP bone scintigraphy, including a patient with myeloma and a patient with a metastatic bone tumor from esophageal cancer. Bone scintigraphy with a 99mTc-phosphate complex reflects osteoblastic activity in the bone tissue surrounding the tumor, whereas the accumulation of FDG is associated with the metabolic activity of the tumor itself. An FDG-PET study can therefore be used as a complementary study for the detection and follow-up of bone tumors when a 99mTc-phosphate bone scintigram is negative.
Sasaki
M
M
Department of Radiology, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
Ichiya
Y
Y
Kuwabara
Y
Y
Otsuka
M
M
Fukumura
T
T
Kawai
Y
Y
Koga
H
H
Masuda
K
K
D000328:Adult; D001859:Bone Neoplasms / Q000000981:diagnostic imaging* / Q000556:secondary; D003847:Deoxyglucose / Q000031:analogs & derivatives*; D005188:False Negative Reactions; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000000981:diagnostic imaging; D012272:Ribs; D013669:Technetium Tc 99m Medronate / Q000031:analogs & derivatives*; D014055:Tomography, Emission-Computed
D019788:Fluorodeoxyglucose F18; C024226:technetium Tc 99m hydroxymethylene diphosphonate; D003847:Deoxyglucose; D013669:Technetium Tc 99m Medronate